Skip to Content

A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects with Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease

Objective
This is a clinical trial of the investigational medication abiraterone acetate and prednisone, both of which will be administered by mouth in addition to current hormone therapy.
IRB Protocol Number
11-1017
Principal Investigator(s)
E. DAVID CRAWFORD

Cancer Trials

  • Prostate Cancer
Sponsor(s)
Centocor, Inc.
Contact
CLIFFORD JONES at 720-848-0684
or CLIFFORD.JONES@UCDENVER.EDU
Eligibility and Other Participant Information
What To Expect : A screening period determines eligibility. A treatment period that can last up to 24 months depending on disease progression. A follow-up period may consist of physician contact, clinic visits, and/or phone contact. // Eligibility criteria include men 18 years or older who have castration-resistant, non-metastatic prostate cancer, a rising PSA, and have no previous treatment with chemotherapy.